IL6 and melanoma: For example, high levels of IL-6, a typical inflammatory cytokine, are considered a risk factor for irAE, and tocilizumab, an anti-IL-6 receptor monoclonal antibody, can reportedly prevent irAEs in patients with melanoma undergoing ICI therapy (Dimitriou et al., 2021).